Monday, May 01, 2017 11:32:44 AM
2Q’18
? CTL-019 treatment mainly in relapsed/refractory patients with poor prognosis:
10% B-ALL patients and 30% DLBCL patients
? Max 20% penetration of the ALL market in Europe and 30% in US; max 15%
penetration of the DLBCL market in Europe and 25% in US by 2025
? Price for single treatment: $600,000
? OXB receives 4% royalties
We estimate that Novartis will achieve sales of $2.05bn per annum from CTL-019 by
2025. OXB could, therefore, receive a total of $82.0m in royalties per annum, in
addition to manufacturing revenue.
HTTP://www.hardmanandco.com/docs/default-source/company-docs/oxford-biomedica-documents/31.03.17-delivering-commercial-gene-therapy-vector.pdf
FEATURED Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM
North Bay Resources Announces Mt. Vernon Gold Mine Bulk Sample, Sierra County, California • NBRI • Sep 11, 2024 9:15 AM
One World Products Issues Shareholder Update Letter • OWPC • Sep 11, 2024 7:27 AM
Kona Gold Beverage Inc. Reports $1.225 Million in Revenue and $133,000 Net Profit for the Quarter • KGKG • Sep 10, 2024 1:30 PM